Carcinogenesis, Vol. 23, No. 7, 1185-1192,
July 2002
© 2002 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Prevention of mouse lung tumors by budesonide and its modulation of biomarkers
1 Department of Pathology, Medical College of Ohio, HEB, Room 200F, 3055 Arlington Avenue, Toledo, OH 43614-5806, USA and
2 Chemopreventive Agent Development Research Group, Division of Cancer Chemoprevention, National Cancer Institute, Bethesda, MD 20892, USA
Chemopreventive drugs have the potential to decrease the morbidity and mortality of lung cancer. The development of these drugs could be expedited by the application of surrogate end-point biomarkers that demonstrate chemopreventive efficacy. In this study, the ability of budesonide to prevent lung tumors in mice was characterized further and its effects on biomarkers were determined. Lung tumors were induced in female strain A mice by vinyl carbamate (16 mg/kg) administered once weekly for 2 consecutive weeks. Four weeks later the mice started to receive 0.6, 1.2 or 2.4 mg/kg budesonide continually in the diet until killed at week 20. Budesonide caused a dose-dependent decrease in the multiplicity of lung tumors of 25, 58 and 82%, respectively. Budesonide (2.4 mg/kg diet) administered starting at weeks 4, 10 or 16, decreased tumor multiplicity by 82, 66 and 30% at week 20. Administering 2.4 mg/kg budesonide at weeks 4–20 or 20–35 and killing the mice at week 35 did not significantly decrease the yield of tumors, although both treatment regimens did decrease the size of the tumors and the progression of adenomas to carcinomas. Thus, budesonide delayed the appearance of lung tumors and decreased their growth and progression to carcinomas. To determine the effect of limited exposure to budesonide on biomarkers, it was administered for only 7 days prior to death at week 35. Budesonide decreased the proliferating cell nuclear antigen labeling in lung adenomas, carcinomas, parenchyma and bronchial airways by 87.6, 59.0, 41.1 and 25.4%, respectively. Budesonide treatment also increased the protein level of the p21 and p27 genes and increased the mRNA level of p21. Thus, short-term treatment with budesonide modulated biological and molecular end-points in lung tumors that might be developed further as biomarkers for its clinical chemopreventive efficacy in the lung.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Liby, C. C. Black, D. B. Royce, C. R. Williams, R. Risingsong, M. M. Yore, X. Liu, T. Honda, G. W. Gribble, W. W. Lamph, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis Mol. Cancer Ther., May 1, 2008; 7(5): 1251 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, L. Tao, R. A. Lubet, V. E. Steele, and M. A. Pereira Modulation by budesonide of a CpG endonuclease in mouse lung tumors Carcinogenesis, July 1, 2007; 28(7): 1499 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Alyaqoub, L. Tao, P. M. Kramer, V. E. Steele, R. A. Lubet, W. T. Gunning, and M. A. Pereira Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT) Carcinogenesis, January 1, 2007; 28(1): 124 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. S. Alyaqoub, L. Tao, P. M. Kramer, V. E. Steele, R. A. Lubet, W. T. Gunning, and M. A. Pereira Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT) Carcinogenesis, December 1, 2006; 27(12): 2442 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Balansky, F. D'Agostini, G. Ganchev, A. Izzotti, B. Di Marco, R. A. Lubet, N. Zanesi, C. M. Croce, and S. De Flora Influence of FHIT on benzo[a]pyrene-induced tumors and alopecia in mice: Chemoprevention by budesonide and N-acetylcysteine PNAS, May 16, 2006; 103(20): 7823 - 7828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Conaway, C.-X. Wang, B. Pittman, Y.-M. Yang, J. E. Schwartz, D. Tian, E. J. McIntee, S. S. Hecht, and F.-L. Chung Phenethyl Isothiocyanate and Sulforaphane and their N-Acetylcysteine Conjugates Inhibit Malignant Progression of Lung Adenomas Induced by Tobacco Carcinogens in A/J Mice Cancer Res., September 15, 2005; 65(18): 8548 - 8557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Bauer, A. M. Malkinson, and S. R. Kleeberger Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L685 - L703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lam, J. C. leRiche, A. McWilliams, C. MacAulay, Y. Dyachkova, E. Szabo, J. Mayo, R. Schellenberg, A. Coldman, E. Hawk, et al. A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium Clin. Cancer Res., October 1, 2004; 10(19): 6502 - 6511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Estensen, M. M. Jordan, T. S. Wiedmann, A. R. Galbraith, V. E. Steele, and L. W. Wattenberg Effect of chemopreventive agents on separate stages of progression of benzo[{alpha}]pyrene induced lung tumors in A/J mice Carcinogenesis, February 1, 2004; 25(2): 197 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Gunning, P. M. Kramer, R. A. Lubet, V. E. Steele, D. W. End, W. Wouters, and M. A. Pereira Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777 Clin. Cancer Res., May 1, 2003; 9(5): 1927 - 1930. [Abstract] [Full Text] [PDF]
|
|